Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response.

ABSTRACT:

Background

Ovarian cancers are the second cause of death from gynecological cancers worldwide, due to a late diagnosis combined with the development of resistance to chemotherapy. However, half of these cancers present alterations in Homologous Recombination (HR), making them sensitive to inhibitors of the PARP protein (PARPi), involved in DNA repair. Nevertheless, identifying patients who respond to chemotherapy and selecting those eligible for PARPi remains a challenge for clinicians. In this context, the use of Patient-Derived Tumor Organoids (PDTO) for predictive functional testing represents an interesting prospect for clinical decision making.

Methods

Here we established a panel of 37 long-term PDTO models of various histological subtypes from 31 ovarian cancer patient

SUBMITTER: Thorel L 

PROVIDER: S-EPMC12502492 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature